1163721-04-7

Basic information

• Product Name: 8-(4-amino-3-fluorophenoxy)pyrido[2,3-b]pyrazin-3(4H)-one
• Synonyms: 8-(4-amino-3-fluorophenoxy)pyrido[2,3-b]pyrazin-3(4H)-one
• CAS NO: 1163721-04-7
• Molecular Weight: 272.238
• Mol File: 1163721-04-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 8-(4-amino-3-fluorophenoxy)pyrido[2,3-b]pyrazin-3(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 8-(4-amino-3-fluorophenoxy)pyrido[2,3-b]pyrazin-3(4H)-one(1163721-04-7)
• EPA Substance Registry System: 8-(4-amino-3-fluorophenoxy)pyrido[2,3-b]pyrazin-3(4H)-one(1163721-04-7)

Safety Data

• Hazardous Substances Data: 1163721-04-7(Hazardous Substances Data)

Upstream product

• 1163720-74-8 tert-butyl (2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)carbamate 
• 1163720-60-2 4-(4-N-(tert-butoxycarbonyl)amino-3-fluorophenoxy)-3-nitro-2-aminopyridine 
• 911297-02-4 N-(2-fluoro-4-hydroxyphenyl)carbamic acid tert-butyl ester 
• 6980-08-1 4-chloro-3-nitro-2-pyridinamine 
• 1163720-66-8 4-(4-N-(tert-butoxycarbonyl)amino-3-fluorophenoxy)-2,3-diaminopyridine 
• 399-95-1 4-amino-3-fluorophenol 

Downstream Products

• 1163721-37-6 phenyl 2-fluoro-4-(3-oxo-3,4-dihydropyrido[3,2-b]pyrazin-8-yloxy)phenylcarbamate 
• 1163720-32-8 1-(2-fluoro-4-(3-oxo-3,4-dihydropyrido[2,3-,b]pyrazin-8-yloxy)phenyl)-3-(5-(trifluoromethyl)pyridin-3-yl)urea 
• 1163720-41-9 1-(3-tert-butyl-1-(cyclopropylmethyl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(3-oxo-3,4-dihydropyrido[3,2-b]pyrazin-8-yloxy)phenyl)urea 
• 1234623-43-8 1-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(oxo3,4-dihydropyrido[2,3-b]pyrazin-8-yloxy)phenyl)urea 
• 1163719-53-6 1-(2-fluoro-4-(3-oxo-3,4-dihydropyrido[3,2-b]pyrazin-8-yloxy)phenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea 
• 1163719-52-5 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2-fluoro-4-(3-oxo-3,4-dihydropyrido[3,2-b]pyrazin-8-yloxy)phenyl)urea 

Relevant articles and documents

POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)- 3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea compounds (referred herein as "TBAP compounds") that, inter alia, inhibit RAF (e.g., BRAF, CRAF, etc.). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF, CRAF, etc.); and to treat disorders including: proliferative disorders; cancer (including, e.g., malignant melanoma, colorectal carcinoma, pancreatic adenocarcinoma); inflammation; immunological disorders; viral infections; fibrotic disorders; disorders associated with a mutated form of RAF (e.g., BRAF, CRAF, etc.); disorders ameliorated by the inhibition of RAF (e.g., BRAF, CRAF, etc.); disorders ameliorated by the inhibition of mutant BRAF; disorders ameliorated by the inhibition of BRAF and CRAF; disorders associated with RAS mutations and/or MAPK pathway activation; disorders ameliorated by the inhibition of SRC, p38, FGFRA, VEGFR-2 (KDR), and/or LCK; etc.

PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.